CCM
ITCI

Cinctive Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cinctive Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-140,000
Closed -$18.5M – 491
2025
Q1 		$18.5M Buy
+140,000
New +$17.4M 1.41% 15
2024
Q2 		– Sell
-23,100
Closed -$1.6M – 551
2024
Q1 		$1.6M Buy
+23,100
New +$1.59M 0.07% 236

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cinctive Capital Management's ITCI Position: Q2 2025 in Review

Cinctive Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 140,000 shares — an estimated $18.5M sold.

Cinctive Capital Management first reported a position in ITCI in Q1 2024 and held it in 2 quarters. The position peaked at $18.5M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Cinctive Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 140,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.5M.
  • Cinctive Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 2 quarters.
  • Cinctive Capital Management's Intra-Cellular Therapies Inc. position peaked at $18.5M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Cinctive Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.